Optimizing chemotherapy for advanced non-small cell lung cancer: Focus on docetaxel

Lung Cancer

Volumn 50, Issue SUPPL. 2, 2005, Pages S3-

  Belani, Chandra P ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Carboplatin; Cisplatin; Docetaxel; Non small cell lung cancer cancer

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; GEMCITABINE; IRINOTECAN; MITOMYCIN; NAVELBINE; PACLITAXEL; VINBLASTINE; VINDESINE;

ANOREXIA; AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; FEBRILE NEUTROPENIA; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; META ANALYSIS; MONOTHERAPY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; PRIORITY JOURNAL; QUALITY OF LIFE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VOMITING;

EID: 33645029815     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(05)81567-3     Document Type: Conference Paper

References (27)

1. Jemal A., Tiwari R.C., and Murray T. Cancer statistics, 2004 CA Cancer J Clin 54 2004 8 29
2. Rapp E., Pater J.L., and Willan A. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a Canadian multicenter randomized trial J Clin Oncol 6 1988 633 641
3. Ramalingam S., and Belani C.P. State-of-the-art chemotherapy for advanced non-small cell lung cancer Semin Oncol 31 2004 68 74.
4. Kubota K., Watanabe K., and Kunitoh H. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group J Clin Oncol 22 2004 254 261
5. Fossella F., Pereira J.R., and von Pawel J. Randomized, multinational, phase III study of docetaxeL plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group J Clin Oncol 21 2003 3016 3024
6. Georgoulias V., Papadakis E., and Alexopoulos A. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentee trial Lancet 357 2001 1478 1484
7. Abstract 2528 Fossella F., and Belani C.P. Phase III study (TAX 326) of docetaxel-cisplatin and docetaxel-carboplatin versus vinorelbinecisplatin for the first-Line treatment of advanced/ metastatic non-small cell lung cancer: Analyses in elderly patients Proc Am Soc Clin Oncol 22 2003 629
8. Abstract 7006 Kubota K., Nishiwaki Y., and Ohashi Y. The Four-Arm Cooperative Study (FACS) for advanced non-small-cell lung cancer (NSCLC) J Clin Oncol 22 2004 618s
9. Schiller J.H., Harrington D., and Belani C.P. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92 98
10. Sweeney C.J., Zhu J., and Sandier A.B. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic non-small cell lung carcinoma Cancer 92 2001 2639 2647
11. Abstract 0-098 Rigas J., Dragnev K., and Kerry M. Survival equivalence of non-platinum based and platinum based chemotherapy for advanced non-small cell lung cancer (NSCLC): The results of a multicenter internet-based Phase III randomized study Lung Cancer 49 suppl 2 2005 5
12. Abstract 2505 Groen H., Schramel F.M., and Van der Hoeven J.J.M. Docetaxel and carboplatin once every 3 weeks versus weekly docetaxel in advanced non-small cell lung cancer (NSCLC). An interim analysis of a multicenter phase III trial Proc Am Soc Clin Oncol 22 2003 623
13. Abstract 7066 Lorigan Randomised phase III trial of docetaxel/carboplatin vs MIC/MVP chemotherapy in advanced NSCLC - final results of a British Thoracic Oncology Group trial J Clin Oncol 22 2004 632s
14. Alberola V., Camps C., and Provencio M. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial J Clin Oncol 21 2003 3207 3213
15. Lilenbaum R.C., Herndon J.E., and List M.A. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730) J Clin Oncol 23 2005 190 196
16. Abstract 1162 Sederholm C. Gemcitabine compared with gemcitabine plus carboplatin in advanced non-small cell lung cancer: A phase III study by the Swedish Lung Cancer Study Group Proc Am Soc Clin Oncol 21 2002 291a
17. Georgoulias V., Ardavanis A., and Agelidou A. Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial J Clin Oncol 22 2004 2602 2609
18. Abstract 7000 Kosmidis P., Kalofanos C., and Syrigos K. Paclitaxel and gemcitabine vs. carboplatin and gemcitabine. A multicenter, phase III randomized trial in patients with advanced inoperable non-small cell lung cancer J Clin Oncol 23 2005 621s
19. Kosmidis P., Mylonakis N., and Nicolaides C. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial J Clin Oncol 20 2002 3578 3585
20. Smit E.F., van Meerbeeck J.P., and Lianes P. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975 J Clin Oncol 21 2003 3909 3917
21. D'Addario G., Pintilie M., and Leighl N.B. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature J Clin Oncol 23 2005 2926 2936
22. Abstract 2571 Langer C.J., Vangel M., and Schiller J. Age-specific subanalysis of ECOG 1594: Fit elderly patients (70-80 yrs) with NSCL do as well as younger pts (<70 years) Proc Am Soc Clin Oncol 22 2003 639
23. Abstract 2 Lilenbaum R.C., Herndon J.E., and List M. Single agent versus combination chemotherapy in patients with advanced non-small cell lung cancer: A CALGB randomized trial of efficacy, quality of life and cost-effectiveness Proc Am Soc Clin Oncol 2002 1a
24. Gridelli C., Perrone F., and Gallo C. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial J Natl Cancer Inst 95 2003 362 372
25. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group J Natl Cancer Inst 91 1999 66 72
26. Abstract 0-088 Belani C., Ramalingam S., and Perry M. Phase III randomized trial comparing weekly vs. standard schedules of paclitaxel plus carboplain for advanced non-small cell lung cancer: Analysis of elderly patients Lung Cancer 49 suppl 2 2005 S32
27. Abstract LBA4 Sandler A.B., Gray R., and Brahmer J. Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599 J Clin Oncol 23 2005 2s